No Data
No Data
Cidara Therapeutics Inc. Hits Snag: Delayed 10-K Filing Complicates Capital Raising Efforts
Express News | Needham Reiterates Buy on Cidara Therapeutics, Maintains $25 Price Target
Buy Rating Justified by Cidara Therapeutics' Upcoming Clinical Trials and Expanding Oncology Pipeline
Cidara Therapeutics | 10-Q: Quarterly report
Cidara Therapeutics: Closed a $240M Private Placement Led by RA Cap Management >CDTX
Cidara Therapeutics: Closed a $240M Private Placement Led by RA Cap Management >CDTX
Express News | Cidara Therapeutics Q1 2024 GAAP EPS $(2.28) Misses $(0.20) Estimate, Sales $8.46M Beat $6.30M Estimate